CLEVELAND, Jan. 31, 2013 /PRNewswire/ -- Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds. The FDA Investigational Device Exemption (IDE-15140) allows Arteriocyte and its clinical partners to initiate evaluation of autologous platelet gel (APG) (using the Magellan Autologous Platelet Separator technology) as an adjunctive therapy for autologous skin grafting in patients with thermal injuries. This treatment has been developed in partnership with the United States Telemedicine and Advanced Technology Research Center (TATRC), and the University of Utah Health Science Center and Intermountain Burn Center. Arteriocyte is initiating a series of investigations employing Arteriocyte's Magellan Autologous Platelet Rich Plasma and Bone Marrow Derived Stem Cell Based Therapies for Burn Wounds as part of Arteriocyte's Cellular Therapies for Battlefield Wounds Program. The Magellan System is an FDA 510(k) cleared medical device for the rapid production of Platelet Rich Plasma from blood and bone marrow that can be applied to a surgical site as surgeons deem necessary for their clinical use requirements. Magellan MAR01a technology enables the rapid Operating … Continue reading →

Washington, January 31 (ANI): The Idu-Mishmi community of Arunachal Pradesh and RIWATCH (Research Institute of World's Ancient Traditions Cultures and Heritage) have made a great contribution in studying dormant Mycobacterium in TB that has affected nearly 4 billion people in the world and causing 1.9 million deaths yearly. TB is a huge problem in India. The incidence of this infectious disease is much more higher in Northeast of India and especially Arunachal Pradesh than rest of India. The doctors prescribe drug treatment for months together to the TB patients, however TB recurs leading to death and suffering. It was not clear as to how the bacteria of TB hide in the body from months of drug treatment. Now a new study has reported that the dormant TB hide in bone marrow stem cells to escape from drug treatment. The finding that could help develop better therapy to target the dormant TB bacteria. Dr. Bikul Das, who hails from Sualkuchi in Assam and engaged in doing research on stem cells in Stanford University California is known to RIWATCH and its' parent organization ICCS (International Center for Cultural Studies US) since long. When he was working as a Doctor in Bhutan, he … Continue reading →

By Alex Y. Vergara DR. VICKI Belo ARNOLD ALMACEN Is the elusive search for the fountain of youth over? Vicki Belo, one of the countrys leading beauty doctors, thinks so, as she recently unveiled her latest weapons in the fight against aging: intradermal (ID) and intravenous (IV) stem cell treatments. Developed by Russian doctors in Moscow after more than a decade of research, ID treatment, much like Botox, is injected directly on specific points of the face and neck to supposedly facilitate faster skin regeneration, tighten sagging muscles and promote the production of collagen and elastin, two of the skins most important building blocks. As we age, our skin tends to lose elasticity, said Belo. Since we dont produce as much collagen and elastin as we used to, our faces soon lose fat and become hollow. Wrinkles also start to deepen and permanently set in. This may sound a bit scary, but the stem cells Belo uses, unlike those used in a number of clinics abroad, including a famous one in Germany, dont come from animals like sheep. They are not sourced from embryos either. In a way, we pioneered stem cell therapy in the Philippines by using a persons … Continue reading →

New Delhi, Jan. 31: Scientists, using bone marrow samples from members of the Idu Mishmi tribe in Arunachal Pradesh, have discovered the hideout in the human body where tuberculosis bacteria can lie dormant for years. A collaborative study by Indian and US scientists has identified stem cells in the bone marrow that seem to serve as a "protective niche" for TB germs to evade the drugs' action and the human immune system. The study, published yesterday in the journal Science Translational Medicine, relied on samples of bone marrow provided by volunteers among Idu Mishmi tribals who live in a remote mountain range in Arunachal's Lower Dibang Valley. By volunteering to participate in the study, scientists say, this indigenous community has contributed to efforts to resolve a long-standing medicine mystery. While effective antibiotics have been available to treat and cure TB for more than 50 years, TB bacilli remain in the body despite a successful course of treatment and can cause the disease to recur after years or even decades. Now Bikul Das, at the Stanford University Medical Centre, and his collaborators have found that cells called mesenchymal stem cells (MSCs) in the bone marrow appear to provide a "long-term protective" … Continue reading →